| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
42,210,000 |
| Market
Cap: |
143.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.6 - $4.215 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Opthea is a clinical stage biopharmaceutical company, focused on developing therapies for patients with retinal eye diseases. Co.'s OPT 302 is a soluble form of vascular endothelial growth factor receptor 3 in clinical development as a therapy for wet (neovascular) age-related macular degeneration and diabetic macular edema. Co.'s development activities are based on intellectual property portfolio covering key targets for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Co.'s Phase 3 program consists of Study of OPT 302 in combination with Ranibizumab and Combination OPT 302 with Aflibercept Study.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
0.23 (6.34%) 
